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Epidemiological data for 
hepatitis D in Africa
Authors’ reply
Jose Debes and Shemal Shah highlight 
the paucity of data from east Africa, 
one of our major findings. The 
authors draw attention to a study 
from Tanzania, where samples that 
initially tested positive for antibodies 
against hepatitis D virus by a 
commercial assay did not test positive 
on retesting with a second assay.1 
The performance of the second assay 
relative to the first was unknown. 
Given that the first assay was used 
widely in the studies included in 
our analysis without confirmation 
by a second assay, we elected not to 
take retesting into account for the 
study from Tanzania and to maintain 
consistency with data available from 
the other studies. Further research 
is required to determine whether 
there is a generalisable issue with 
the specificity of hepatitis D virus 
antibody testing in Africa. We agree 
that considerations of assay specificity 
are important in this setting, as also 
seen with the detection of antibodies 
against hepatitis C virus.2 In the case 
of hepatitis B virus testing, however, 
there appears to be an issue of 
reduced sensitivity, rather than 
reduced specificity, when using rapid 
screening tests for HBsAg.3
We are less clear about the assertion 
that suppression of hepatitis B virus 
replication with antiviral therapy 
makes hepatitis D virus positivity less 
likely. The hepatitis D virus particle 
comprises an RNA genome, a single 
hepatitis D virus-encoded antigen, 
and a lipoprotein envelope provided 
by hepatitis B virus. Nucleoside 
and nucleotide analogues inhibit 
replication of hepatitis B virus, but 
rarely lead to HBsAg loss. Although 
long-term suppression of hepatitis B 
virus replication might possibly also 
result in the suppression of hepatitis D 
virus replication, evidence in support of 
this statement is at best conflicting.4,5 It 
is nonetheless important to emphasise 
that eradication of hepatitis D virus at 
the population level must ultimately 
rely on the implementation of effective 
policies to reduce hepatitis B virus 
transmission.
Edouard Tuaillon and colleagues 
describe the use of dried blood spots 
(DBSs) for the detection of antibodies 
against hepatitis D virus in a large 
survey of adult volunteers in Burkina 
Faso. Consistent with our conclusions,6 
the authors observed localised clusters 
of endemicity, and exploration of 
the risk factors for hepatitis D virus 
infection in the same population 
would be of interest. The report 
indicates that DBS offer a promising 
tool for obtaining representative 
measurements of the prevalence of 
hepatitis D virus. Validation data will 
increase confidence in the reliability 
of DBS testing for antibodies against 
hepatitis D virus. Important technical 
challenges remain: use of elutes from 
DBS samples reduces overall testing 
sensitivity, and whether DBS testing is 
a suitable method for hepatitis D virus 
RNA detection in Africa remains to be 
demonstrated.
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